Document is current
Any future updates will be listed below
-
Authors
Liberale, Luca https://orcid.org/0000-0003-1472-7975
Duncker, Dirk Jan https://orcid.org/0000-0003-2836-2241
Hausenloy, Derek John
Kraler, Simon https://orcid.org/0000-0002-8245-7287
Bøtker, Hans Erik
Podesser, Bruno Karl
Heusch, Gerd https://orcid.org/0000-0001-7078-4160
Kleinbongard, Petra https://orcid.org/0000-0003-3576-3772
- License Information
-
More Information
Article History
Accepted: 30 April 2025
First Online: 22 June 2025
Competing interests
: L.L. is a co-inventor on the international patent WO/2020/226993 filed in April 2020. The patent relates to the use of antibodies that specifically bind to IL-1α to reduce various sequelae of ischaemia–reperfusion injury to the central nervous system. L.L. has received speaker fees from Daiichi-Sankyo, he is a counsellor of the European Society for Clinical Investigation and has received funding from the Italian Ministry of Health, the Novartis Foundation for Medical-biological Research and the Swiss Heart Foundation. D.J.H. has received consultant fees from Boehringer Ingelheim International and Faraday Pharmaceuticals, has received honoraria from Servier, and has received research funding from AstraZeneca, Merck Sharp & Dohme Corp and Novo Nordisk. S.K. has received speaker fees from Roche Diagnostics and the Foundation for Cardiovascular Research – Zurich Heart House and has received travel support from 4TEEN4 Pharmaceuticals, European Atherosclerosis Society, European Society of Cardiology, European Society of Clinical Investigation, Foundation for Cardiovascular Research – Zurich Heart House, PAM Theragnostics and Sphingotec. The other authors declare no competing interests.
